Assenagon Asset Management S.A. Boosts Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assenagon Asset Management S.A. increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1,196.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 336,237 shares of the medical equipment provider’s stock after purchasing an additional 310,301 shares during the period. Assenagon Asset Management S.A. owned approximately 0.49% of Lantheus worth $32,817,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC raised its position in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after acquiring an additional 435,445 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Lantheus in the fourth quarter worth $36,183,000. Finally, Keybank National Association OH purchased a new position in Lantheus in the fourth quarter worth $27,526,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on LNTH. Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $132.67.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director now owns 318,650 shares of the company’s stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Lantheus Trading Down 0.8%

Shares of LNTH opened at $80.14 on Friday. The stock has a market cap of $5.54 billion, a P/E ratio of 13.33 and a beta of 0.11. The company has a 50-day moving average of $89.13 and a two-hundred day moving average of $91.46. Lantheus Holdings, Inc. has a 12-month low of $73.11 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business’s revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.69 EPS. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.